- This study addressed evolving diagnostic and therapeutic approaches for Aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD).
- Researchers retrospectively analyzed clinical data from 98 French centers, including 769 AQP4+NMOSD and 957 MOGAD patients.
- Mean annualized relapse rates in AQP4+NMOSD decreased from 0.45 (2010-2014) to 0.04 (2022-2023), with p < 0.001.
- The authors concluded that this registry showed reduced diagnosis time, decreased disease activity, and evolving therapeutic strategies over 15 years.
- These findings offer valuable insights into real-world clinical practice and treatment patterns for AQP4+NMOSD and MOGAD in France.
Evolving Management of AQP4+NMOSD and MOGAD
Aquaporin-4 immunoglobulin G-seropositive neuromyelitis optica spectrum disorder (AQP4+NMOSD) and myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) are distinct autoimmune conditions of the central nervous system that require specific management apart from multiple sclerosis [1, 2, 3]. While both involve inflammatory demyelination, their differing immunopathologies have spurred the development of targeted immunotherapies, including monoclonal antibodies, that have reshaped the treatment landscape [4, 5, 6]. Despite these advances, large-scale, real-world data on how these changes have affected clinical practice and patient outcomes have been limited [7]. A recent nationwide study from France now provides a detailed account of these trends over the past 15 years.
A National View of Rare Autoimmune Conditions
To illuminate the real-world management of these rare disorders, researchers analyzed data from the NOMADMUS cohort, a comprehensive French national registry. The retrospective study drew upon clinical, imaging, and therapeutic data collected from a network of 98 centers across France. The analysis, with data current as of June 8, 2024, focused on patients classified by serologic status as having either AQP4+NMOSD or MOGAD. This serological stratification is critical, as it allows for a direct comparison of the distinct disease trajectories and treatment responses associated with each specific autoantibody.
Cohort Demographics and Disease Burden
The NOMADMUS registry provided a substantial sample for analysis, including 769 patients with AQP4+NMOSD and 957 with MOGAD. Across the combined cohort, there was a clear female predominance (68.6%), and the mean age at disease onset was 37.4 years (standard deviation 18.3). A key finding emerged regarding long-term disability. The study found that the risk to reach an Expanded Disability Status Scale (EDSS) score of 3 or 6 was lower in patients with MOGAD compared with AQP4+NMOSD patients. The EDSS is a standard tool for quantifying disability in central nervous system diseases, where a score of 3.0 represents moderate disability and 6.0 indicates the need for walking assistance. This finding suggests a more favorable long-term prognosis for disability accumulation in MOGAD, a crucial factor for patient counseling and management.
Declining Relapse Rates Over Time
A central finding from the analysis is a marked reduction in disease activity for both conditions over the last decade. For patients with AQP4+NMOSD, the mean annualized relapse rate fell from 0.45 (95% confidence interval 0.41-0.48) in the 2010-2014 period to 0.04 (95% CI 0.03-0.05) in 2022-2023. This dramatic decrease was statistically significant (p < 0.001, Welch's t test). A similar improvement was observed in the MOGAD group, where the mean annualized relapse rate declined from 0.21 (95% CI 0.18-0.24) to 0.03 (95% CI 0.02-0.04) over the same timeframes, also a statistically significant reduction (p < 0.001). These data demonstrate a substantial improvement in disease control in real-world clinical practice, likely reflecting the adoption of more effective maintenance therapies.
Impact on Diagnosis and Treatment Strategies
The improvements in disease activity are paralleled by significant shifts in clinical practice. The NOMADMUS registry data revealed a reduction in the time to diagnosis for both AQP4+NMOSD and MOGAD over the 15-year study period. This acceleration in diagnosis allows for earlier initiation of appropriate immunotherapy, which likely contributes to the observed decline in relapse rates. Concurrently, the study documented a clear evolution in the therapeutic strategies used in France, reflecting the integration of new evidence and targeted treatments into routine care. By capturing data from a large, nationwide cohort, this collaborative effort provides valuable, real-world insights into how clinical practice has adapted, confirming that changes in diagnostic and treatment patterns have corresponded with improved disease control for patients with these rare neuroinflammatory disorders.
References
1. Wingerchuk DM, Banwell B, Bennett JL, et al. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology. 2015. doi:10.1212/wnl.0000000000001729
2. Bruijstens AL, Lechner C, Flet‐Berliac L, et al. E.U. paediatric MOG consortium consensus: Part 1 – Classification of clinical phenotypes of paediatric myelin oligodendrocyte glycoprotein antibody-associated disorders. European Journal of Paediatric Neurology. 2020. doi:10.1016/j.ejpn.2020.10.006
3. Medina R, Derias A, Lakdawala M, Speakman S, Lucke-Wold B. Overview of emerging therapies for demyelinating diseases.. World journal of clinical cases. 2024. doi:10.12998/wjcc.v12.i30.6361
4. Zammar K, Safan A, Abushalbak DJ, et al. Monoclonal antibody efficacy in seropositive vs seronegative NMOSD: systematic review and meta-analysis.. Journal of neuroimmunology. 2026. doi:10.1016/j.jneuroim.2026.578945
5. Song Y, Li J, Wu Y. Evolving understanding of autoimmune mechanisms and new therapeutic strategies of autoimmune disorders. Signal Transduction and Targeted Therapy. 2024. doi:10.1038/s41392-024-01952-8
6. Aletaha D, Kerschbaumer A, Kastrati K, et al. Consensus statement on blocking interleukin-6 receptor and interleukin-6 in inflammatory conditions: an update. Annals of the Rheumatic Diseases. 2022. doi:10.1136/ard-2022-222784
7. Häußler V, Trebst C, Engels D, et al. Real-world multicentre cohort study on choices and effectiveness of immunotherapies in NMOSD and MOGAD. Journal of Neurology Neurosurgery & Psychiatry. 2024. doi:10.1136/jnnp-2024-334764